Ethereum (ETH) Outperformed Bitcoin (BTC) During ETF Approval Week (Market Watch)
In what appears to e a sell-the-news event, the ETF approvals in the US led to price declines for BTC.
Bitcoin has calmed at around $43,000 after the recent volatility propelled by the US Securities and Exchange Commission and the launch of 11 spot ETFs.
On a weekly scale, though, BTC is in the red, unlike most cryptocurrencies, such as ETH, which has soared by double digits.
BTC Down on ETF Approval Week
After years and years of delaying and rejecting countless applications, the US securities regulator finally greenlighted spot Bitcoin ETFs on Wednesday, and the products reached the markets a day later.
The whole development didn’t go without a few downturns, including a hack and a controversial statement by the SEC’s chair, Gary Gensler. This resulted in enhanced volatility for the underlying asset, which soared to over $49,000 on Thursday after the ETFs went live and slumped by more than seven grand in the next 36 hours.
The weekend has been a lot less eventful. BTC recovered some of the losses and has remained in a tighter range of around $43,000 for the past two days or so. Nevertheless, the asset is down by more than 2% weekly, which means that its market cap has slipped to $840 billion.
Its dominance over the altcoins has been reduced to under 50%. The metric has shed more than 3% in the past week or so, as it was way above 53%.
ETH Outperforms
While BTC has declined during the week it saw multiple ETFs approved, Ethereum has gone in the other direction, perhaps fueled by hype that it will also have exchange-traded products launching at some point. ETH has risen by more than 13% on a weekly scale and currently trades above $2,500.
Tron and Chainlink have posted similar gains on a weekly scale. Polkadot, Avalanche, Solana, Polygon, Litecoin, and Dogecoin follow suit. In fact, BNB is the only top 10 alt with a minor daily decline.
The total crypto market cap is up by $40 billion since last Sunday but down by more than $80 billion since the peak on Thursday.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
